Image Place holder

Solmaz Sahebjam, MD


Specialty: Medical Oncology
Program: Neuro-Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Sahebjam is a Medical Oncologist/Neuro-Oncologist with research interest in development of new anti-cancer drugs, particularly for primary and metastatic brain tumors. Her clinical practice is devoted solely to treatment of patients with primary central nervous systems tumors (malignant gliomas and primary central nervous system lymphomas) and brain metastases.  Dr. Sahebjam holds boards from the following: Medical Oncology from Royal College of Physicians and Surgeons of Canada, Medical Oncology from  European Society of Medical Oncology, Medical Oncology from American Board of Internal Medicine, Internal Medicine from American Board of Internal Medicine, and Internal Medicine from Royal College of Physicians and Surgeons of Canada.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • McGill University, Canada - Medical Oncology
  • Shriner's Hospital, McGill University - Research Fellowship
  • University of Ottawa, Canada - Internal Medicine
  • Princess Margaret Hospital/University of Toronto - New Drug Development, Neuro-Oncology

Residency:

  • Lincoln Medical Center/Saint Vincent Hospital - Internal Medicine

Medical School:

  • Iran University of Medical Sciences, Tehran, Iran - MD
Participating Trials

CLINICAL TRIAL 18574
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
Condition: Neurologic Oncology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 17978
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) with MK-3475 and Bevacizumab in Patients with Recurrent High Grade Gliomas
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18647
A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma
Condition: Neurologic Oncology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Placebo; Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18832
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Condition: Multiple
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465
Open

CLINICAL TRIAL 18093
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer
Condition: Neurologic Oncology
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 18093
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer
Condition: Neurologic Oncology
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 17932
A Phase 1a/1b Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
Condition: Gastrointestinal Tumor
Intervention: BAY 43-9006 (Sorafenib); GSK1120212 (Trametinib); Sorafenib; Trametinib
Open

CLINICAL TRIAL 18345
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Condition: Genitourinary
Intervention: MK-3475 (Keytruda); Ziv-aflibercept
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18322
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: BLU-554
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18825
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Condition: Multiple
Intervention: XMT-1522
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18660
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Condition: Neurologic Oncology
Intervention: GSK2256098; Vismodegib (Erivedge)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition: Gastrointestinal Tumor
Intervention: MGD007
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampsonc JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neurooncol. 2017 Oct. Pubmedid: 29106665.
  • Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Immunotherapy and radiation in glioblastoma. J Neurooncol. 2017 May. Pubmedid: 28567588.
  • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun;133(2):331-338. Pubmedid: 28466250.
  • Groshev A, Padalia D, Patel S, Garcia-Getting R, Sahebjam S, Forsyth PA, Vrionis FD, Etame AB. Clinical outcomes from maximum-safe resection of primary and metastatic brain tumors using awake craniotomy. Clin Neurol Neurosurg. 2017 Jun;157:25-30. Pubmedid: 28384595.
  • Sahebjam S, Forsyth PA, Smalley KS, Tran ND. Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies. Cancer Control. 2017 Jan;24(1):42-46. Pubmedid: 28178711.
  • Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neurooncol. 2017 Jan;19(1):89-98. Pubmedid: 27580889. Pmcid: PMC5193027.
  • Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.
  • Smalley KS, Fedorenko IV, Kenchappa R, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer. 2016 Sep;139(6):1195-1201. Pubmedid: 27084046. Pmcid: PMC4939138.
  • Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA. A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Res. 2016 Oct;26(5):481-486. Pubmedid: 27285292. Pmcid: PMC5502096.
  • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
  • Ahmed KA, Sarangkasiri S, Chinnaiyan P, Sahebjam S, Yu HH, Etame AB, Rao NG. Outcomes Following Hypofractionated Stereotactic Radiotherapy in the Management of Brain Metastases. Am J Clin Oncol. 2016 Aug;39(4):379-383. Pubmedid: 24755663.
  • Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct;33(28):3186-3192. Pubmedid: 26282642. Pmcid: PMC4857195.
  • Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Can J Neurol Sci. 2013 Mar;40(2):241-246. Pubmedid: 23419575.
  • McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013 Jun;15(3):289-301. Pubmedid: 23344797.
  • Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist. 2013 Apr;17(8):1090-1099. Pubmedid: 22851551. Pmcid: PMC3425527.
  • Sahebjam S, McNamara M, Mason WP. Management of glioblastoma in the elderly. Clin Adv Hematol Oncol. 2012 Jun;10(6):379-386. Pubmedid: 22895239.
  • Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH, Panasci LC. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer. 2011 Oct;105(9):1342-1345. Pubmedid: 21970880. Pmcid: PMC3241562.
  • Atmuri V, Martin DC, Hemming R, Gutsol A, Byers S, Sahebjam S, Thliveris JA, Mort JS, Carmona E, Anderson JE, Dakshinamurti S, Triggs-Raine B. Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol. 2009 Jun;27(8):653-660. Pubmedid: 18762256.
  • Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum. 2007 Mar;56(3):905-909. Pubmedid: 17328064.
  • Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006 Oct;39(4):901-906. Pubmedid: 16730480.
  • Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol. 2005 Jun;166(6):1733-1740. Pubmedid: 15920158. Pmcid: PMC1602404.
  • Najmabadi H, Cucci RA, Sahebjam S, Kouchakian N, Farhadi M, Kahrizi K, Arzhangi S, Daneshmandan N, Javan K, Smith RJ. GJB2 mutations in Iranians with autosomal recessive non-syndromic sensorineural hearing loss. Hum Mutat. 2002 May;19(5):572. Pubmedid: 11968091.
  • Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, Amirizadeh N, Karimi-Nejad MH. The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001 Aug;25(3):285-296. Pubmedid: 11570721.